Nama's AI scorecard currently rates Bio-Techne Buy (7.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is TECH's P/E ratio?

Bio-Techne trades at a trailing price-to-earnings ratio of 37.7.

When does TECH report earnings?

Bio-Techne's next scheduled report is on Nov 9, 2026. Analysts expect EPS of $0.45.

What is the TECH price target?

The median analyst price target from 10 analysts is $73.00, with a range of $50.00 – $73.00.

Is TECH Shariah compliant?

Nama's AAOIFI-style screen reads Bio-Techne as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Does TECH pay a dividend?

Yes — Bio-Techne's dividend yield is 0.4%.

Nama Insights

Bio-Techne (TECH)

Healthcare · Biotechnology · NASDAQ

S&P 500

Bio-Techne (TECH) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $11.43B, a trailing price-to-earnings ratio of 37.7 and a free-cash-flow yield of 2.3%. Over the most recent reported fiscal year, revenue declined 0.4% and free cash flow per share grew 4.4%. Nama's AI scorecard rates it Buy, 7.2 out of 10. On 12-month momentum it ranks in the rising band of its market.

AI scorecard

Buy · 7.2/10

Clearly positive, short of the top band. As of Nov 7, 2026.

Momentum

Rising · +24.7% over 12 months ex. last

Second-best fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-44.3%

How far the last close sits under the highest price of the past five years.

Market cap	$11.43B
Trailing P/E	37.7
Price / book	5.4
Price / sales	9.4
FCF yield	2.3%
Dividend yield	0.4%
Gross margin	65.8%
Operating margin	22.4%
Net margin	15.0%
Revenue growth (YoY)	-0.4%
Revenue growth (3-yr annual)	+2.2%
EPS growth (YoY)	+0.0%
FCF/share growth (YoY)	+4.4%
Beta	1.3
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

TECH earnings

Next report: Nov 9, 2026 (Q1 2027, EPS estimate $0.45). Beat the EPS estimate in 1 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q4 2026	Aug 12, 2026	$0.52	$0.52	+0.0%	$321.19M
Q3 2026	May 6, 2026	$0.53	$0.53	+0.0%	$311.42M
Q2 2026	Feb 4, 2026	$0.46	$0.43	+7.0%	$295.88M
Q1 2026	Nov 5, 2025	$0.42	$0.42	+0.0%	$286.56M

TECH analyst price target

Median target $73.00 from 10 analysts, ranging $50.00 – $73.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live TECH data on Nama Insights →

Recent Congressional trades

Bio-Techne trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
April McClain Delaney	House	Sell	$1,001 - $15,000	May 6, 2026
April McClain Delaney	House	Sell	$1,001 - $15,000	Apr 6, 2026
April McClain Delaney	House	Sell	$1,001 - $15,000	Mar 10, 2026
April McClain Delaney	House	Sell	$1,001 - $15,000	Feb 2, 2026
April McClain Delaney	House	Buy	$1,001 - $15,000	Jan 5, 2026
April McClain Delaney	House	Buy	$1,001 - $15,000	Jan 5, 2026
April McClain Delaney	House	Buy	$1,001 - $15,000	Nov 4, 2025
April McClain Delaney	House	Sell	$1,001 - $15,000	Sep 2, 2025
April McClain Delaney	House	Sell	$1,001 - $15,000	Jul 2, 2025
Julie Johnson	House	Sell	$1,001 - $15,000	May 14, 2025
Rob Bresnahan	House	Sell	$1,001 - $15,000	May 8, 2025
April McClain Delaney	House	Buy	$1,001 - $15,000	May 2, 2025

TECH FAQ

Is TECH a buy?: Nama's AI scorecard currently rates Bio-Techne Buy (7.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is TECH's P/E ratio?: Bio-Techne trades at a trailing price-to-earnings ratio of 37.7.
When does TECH report earnings?: Bio-Techne's next scheduled report is on Nov 9, 2026. Analysts expect EPS of $0.45.
What is the TECH price target?: The median analyst price target from 10 analysts is $73.00, with a range of $50.00 – $73.00.
Is TECH Shariah compliant?: Nama's AAOIFI-style screen reads Bio-Techne as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.
Does TECH pay a dividend?: Yes — Bio-Techne's dividend yield is 0.4%.